DCT

3:26-cv-04286

Sun Pharmaceutical Industries Ltd v. Solaris Pharma Corp

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 3:26-cv-04286, D.N.J., 04/22/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because the Defendant, Solaris, has a "regular and established place of business" in the district and has "committed an act of infringement" within the district by submitting its Abbreviated New Drug Application (ANDA).
  • Core Dispute: Plaintiff alleges that Defendant's filing of an ANDA to market a generic version of Plaintiff's BromSite® ophthalmic solution constitutes an act of infringement of a reissued patent covering the drug's formulation.
  • Technical Context: The technology relates to ophthalmic formulations of non-steroidal anti-inflammatory drugs (NSAIDs), specifically those designed for sustained release to treat post-operative eye inflammation.
  • Key Procedural History: This is a Hatch-Waxman action triggered by Solaris's submission of ANDA No. 220440 and a corresponding Paragraph IV certification, which asserts that the patent-in-suit is invalid, unenforceable, or will not be infringed by the proposed generic product. The patent-in-suit, RE50,218, is a reissue of U.S. Patent No. 8,778,999. Sun's branded product, BromSite®, is listed in the FDA's Orange Book as being covered by the patent-in-suit.

Case Timeline

Date Event
2009-03-05 Priority Date for U.S. Patent No. 8,778,999 (original patent)
2014-07-15 U.S. Patent No. 8,778,999 Issue Date
2015-06-10 New Drug Application (NDA) for BromSite® submitted
2016-04-08 FDA approval for BromSite® marketing
2021-10-01 Merger becomes effective, transferring patent ownership to Sun India
2024-11-26 U.S. Reissued Patent No. RE50,218 Issue Date
2026-03-11 Solaris sends Paragraph IV Notice Letter to Sun
2026-04-22 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Reissued Patent No. RE50,218 - "Non-Steroidal Anti-Inflammatory Ophthalmic Compositions"

  • Patent Identification: U.S. Reissued Patent No. RE50,218 (the "'218 Patent"), "Non-Steroidal Anti-Inflammatory Ophthalmic Compositions", issued November 26, 2024.

The Invention Explained

  • Problem Addressed: The patent's background section notes that prior ophthalmic delivery systems for the NSAID bromfenac suffered from various drawbacks, implicitly including the need for frequent dosing, which can affect patient compliance and therapeutic consistency '218 Patent, col. 1:20-29 Other formulations were shown to have a significant drop in concentration in the eye after twelve hours, consistent with a twice-daily dosing schedule '218 Patent, col. 4:51-58
  • The Patented Solution: The invention is a topical ophthalmic composition that combines bromfenac with a "flowable mucoadhesive polymer" carrier, such as polycarbophil '218 Patent, abstract '218 Patent, col. 2:21-24 This polymer system is designed to have a low viscosity in the bottle for easy administration as a drop, but it gels upon contact with the eye's tear fluid. This gelling action increases the formulation's residence time on the ocular surface, allowing for sustained release of the bromfenac. The patent asserts that this leads to unexpectedly high absorption and retention of the drug in the aqueous humor, enabling a less frequent, once-per-day dosing regimen '218 Patent, col. 4:3-14 '218 Patent, col. 5:58-63
  • Technical Importance: The patented solution offers a potential improvement in patient compliance and therapeutic effect by enabling a once-daily dosing schedule for a topical ophthalmic NSAID, a significant convenience over twice-daily alternatives '218 Patent, col. 4:5-14

Key Claims at a Glance

The complaint asserts infringement of the '218 Patent generally without specifying claims Compl. ¶24 Compl. ¶53 Independent claim 1 is representative of the core composition:

  • A topical ophthalmic composition formulated for application to the eye,
  • said composition comprising a therapeutically effective amount of bromfenac and a flowable cross-linked carboxy-containing polycarbophil mucoadhesive polymer,
  • wherein the composition has a viscosity in the range of about 1,000 to about 3,400 cps and a pH of about 7.4 to about 8.5,
  • wherein the viscosity is measured with a Brookfield cone and plate viscosity DV-II+ with the spindle No. CP-52 at 6 rpm.

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Solaris Pharma Corporation's proposed "generic bromfenac ophthalmic solution, 0.075%," which is the subject of ANDA No. 220440 Compl. ¶¶2, 8

Functionality and Market Context

  • The complaint alleges that Solaris's product is a generic version of Sun's commercially successful product, BromSite® (bromfenac ophthalmic solution), 0.075% Compl. ¶1 As a generic equivalent, it is intended for the same therapeutic uses, namely the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. The complaint states that upon approval, Solaris intends to manufacture, use, offer for sale, and import this generic product in the United States, positioning it as a direct competitor to BromSite® Compl. ¶8

IV. Analysis of Infringement Allegations

The complaint makes general allegations of infringement typical in a Hatch-Waxman case, stating that the submission of ANDA No. 220440 for a product covered by the '218 Patent is an act of infringement under 35 U.S.C. § 271(e)(2) Compl. ¶30 The infringement theory is based on the ANDA product being a generic copy of BromSite®, which is itself alleged to be an embodiment of the patented invention. The following table summarizes the inferred allegations for a representative claim.

'218 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A topical ophthalmic composition formulated for application to the eye... Solaris's ANDA product is a proposed "generic bromfenac ophthalmic solution, 0.075%" intended for use in the eye. ¶8 col. 1:14-17
...comprising a therapeutically effective amount of bromfenac... The ANDA Product is identified as a "bromfenac ophthalmic solution, 0.075%," which is a therapeutically effective concentration. ¶8 col. 2:56-65
...and a flowable cross-linked carboxy-containing polycarbophil mucoadhesive polymer... As a generic version of BromSite®, which is based on the DuraSite® delivery system, the ANDA product is alleged to contain a bioequivalent polymer system that meets this description. ¶1; ¶22 col. 9:45-49
...wherein the composition has a viscosity in the range of about 1,000 to about 3,400 cps... The complaint does not specify the viscosity of the ANDA product, but alleges it is a generic copy that infringes, from which it can be inferred that it is alleged to have the claimed viscosity. ¶1; ¶31 col. 9:49-54
...and a pH of about 7.4 to about 8.5... The complaint does not specify the pH of the ANDA product, but alleges infringement, from which it can be inferred that the pH is alleged to fall within the claimed range. ¶1; ¶31 col. 9:33-34

No probative visual evidence provided in complaint.

  • Identified Points of Contention:
    • Scope Questions: A central dispute will be whether the specific formulation of Solaris's ANDA product meets every limitation of the asserted claims. The case may raise the question of whether the polymer used in the ANDA product, even if bioequivalent, is structurally and functionally identical to the "flowable cross-linked carboxy-containing polycarbophil mucoadhesive polymer" as defined by the patent.
    • Technical Questions: The litigation will likely focus on a detailed comparison of the physical and chemical properties of the ANDA product against the claim limitations. This raises the question of what evidence will show that Solaris's product possesses a viscosity and pH within the claimed ranges of "about 1,000 to about 3,400 cps" and "about 7.4 to about 8.5," respectively, when measured according to the method specified in the claim.

V. Key Claim Terms for Construction

  • The Term: "flowable cross-linked carboxy-containing polycarbophil mucoadhesive polymer"

  • Context and Importance: This term defines the novel delivery vehicle, which is the core of the claimed invention. Its construction will be critical, as Solaris may argue its polymer system, while achieving a similar result, is technically distinct and falls outside this definition. Practitioners may focus on this term because it is a long, multi-part definition that offers several potential avenues for a non-infringement argument.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification refers to the polymer carrier as including "lightly crosslinked polymers of acrylic acid or the like" and explicitly lists "polycarbophil, or Carbopols®, dextran, cellulose derivatives," and other polymers, suggesting the term could encompass a class of materials with similar properties '218 Patent, col. 9:40-44
    • Evidence for a Narrower Interpretation: The patent frequently and specifically references "polycarbophil" and the "DuraSite®" system by name, and incorporates by reference a patent describing that specific system '218 Patent, col. 5:34-40 A defendant could argue the term should be construed more narrowly to the specific embodiments and commercial systems emphasized in the specification.

  • The Term: "about" (as used in "about 1,000 to about 3,400 cps" and "about 7.4 to about 8.5")

  • Context and Importance: The word "about" introduces flexibility into the numerical ranges for viscosity and pH. The scope of this flexibility will be a key point of dispute, as it could determine whether Solaris's product, if its properties are near the boundaries of the ranges, is found to infringe.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: A plaintiff may argue that "about" should be interpreted by a person of ordinary skill in the art to include values that are functionally equivalent and achieve the same sustained-release benefit, reflecting the inherent variability in pharmaceutical measurements.
    • Evidence for a Narrower Interpretation: A defendant may argue that the term "about" should be given a narrow interpretation, perhaps tied to the precision of the measurement instruments described, and that the patentee intended to claim the ranges with a high degree of specificity. The patent provides specific viscosity values in its examples (e.g., "1500 cps"), which could be used to argue for a more precise reading of the claimed ranges '218 Patent, Table 2

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement. It claims Solaris will induce infringement by encouraging the use of its generic product in a manner that infringes the '218 Patent Compl. ¶53 It alleges contributory infringement on the basis that Solaris's product is especially made for an infringing use and is not a staple article of commerce with substantial non-infringing uses Compl. ¶56
  • Willful Infringement: Willfulness is alleged based on Solaris having actual notice of the '218 Patent, at the latest from its listing in the Orange Book, and deliberately preparing to infringe Compl. ¶44 Compl. ¶49

VII. Analyst's Conclusion: Key Questions for the Case

  • Bioequivalence vs. Literal Infringement: The central issue is whether Solaris's ANDA product, which must be bioequivalent to BromSite® for FDA approval, also literally meets every limitation of the asserted patent claims. A key question will be one of structural and functional identity: does the polymer in Solaris's formulation fall within the specific definition of a "cross-linked carboxy-containing polycarbophil," and do the product's physical properties (viscosity, pH) fall within the claimed numerical ranges?
  • Claim Scope and Validity: A core legal battle will be one of definitional scope: how broadly will the court construe the term "polycarbophil" and the numerical ranges modified by "about"? The outcome of this construction will likely determine infringement. Concurrently, Solaris's Paragraph IV certification raises the question of patent validity: are the claims of the '218 Patent, a reissue of a 2014 patent, truly novel and non-obvious in light of the prior art at the time of the original filing?
Loading Complaint